1-Ethoxypropan-2-amine hydrochloride | 1185304-14-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Ethoxypropan-2-amine hydrochloride
• 英文别名: 1-ethoxypropan-2-amine;hydrochloride
• CAS: 1185304-14-6
• 化学式: C5H14ClNO
• mdl: MFCD09879167
• 分子量: 139.62
• InChiKey: UMXZWKSCBDODJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

文献信息

• [EN] SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS<br/>[FR] BENZIMIDAZOLES SUBSTITUÉS, PRÉPARATION ET UTILISATION DE CEUX-CI EN TANT QU'AGENTS PHARMACEUTIQUES
  申请人：NEOMED INST

  公开号：WO2017024412A1

  公开（公告）日：2017-02-16

  This application relates to substituted benzimidazoles of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application also relates to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasm, including tumors and/or cancers.

  本申请涉及到式(I)的取代苯并咪唑化合物，包括它们的组合物以及它们在治疗疾病和病况中的用途，其中需要抑制溴结构域。例如，本申请涉及到取代苯并咪唑化合物及其作为溴结构域抑制剂的用途。本申请还涉及到治疗或预防增生性疾病、自身免疫性疾病、炎症性疾病、皮肤疾病以及新生物，包括肿瘤和/或癌症。
• PYRROLOPYRAZINE KINASE INHIBITORS
  申请人：Chen Shaoqing

  公开号：US20130059834A1

  公开（公告）日：2013-03-07

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用新型吡咯吡嗪衍生物（式I）的使用，其中变量如此处所述，其抑制JAK和SYK并且适用于治疗自身免疫和炎症性疾病。
• Substituted benzimidazoles, their preparation and their use as pharmaceuticals
  申请人：NEOMED Institute

  公开号：US10703740B2

  公开（公告）日：2020-07-07

  This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.

  本申请涉及取代的苯并咪唑、包含它们的组合物以及它们在治疗需要抑制溴链的疾病和病症中的用途。例如，本申请涉及取代的苯并咪唑类化合物及其作为溴链抑制剂的用途。本申请还涉及增殖性疾病、自身免疫性疾病、炎症性疾病、皮肤疾病和肿瘤（包括肿瘤和/或癌症）的治疗或预防。
• SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Neomed Institute

  公开号：EP3334719A1

  公开（公告）日：2018-06-20
• US8658646B2
  申请人：——

  公开号：US8658646B2

  公开（公告）日：2014-02-25